Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
flucloxacillin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving flucloxacillin 250 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| Subjects receiving flucloxacillin 500 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
| Name | Type | Description |
|---|---|---|
| flucloxacillin 250 mg | DRUG | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| flucloxacillin 500 mg | DRUG | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
Inclusion Criteria: * Healthy volunteers, * Caucasians, * Body Mass Index (BMI) between 19 and 27 kg/m 2; * physically and mentally healthy as judged by means of a medical and standard lab examination; * non-smokers, * ex-smokers or moderate smoker. Exclusion criteria: * medical history, * vital ...
Flucloxacillin is used for bacterial infections. It is a small molecule antibacterial agent in the infectious disease therapeutic area. GSK plc, which trades under the ticker GSK, is developing it. Clinical work to date has focused on bacterial infection indications rather than viral or fungal conditions.
Flucloxacillin is developed by GSK plc, which trades on the New York Stock Exchange under the ticker GSK. GSK is the sponsor associated with the clinical development program for this antibacterial small molecule in bacterial infections.
Flucloxacillin is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 24 participants and was conducted in Germany. It is an investigational agent in clinical development for bacterial infections.
Flucloxacillin has been studied in trial NCT00358371, titled Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg). That Phase 1 trial is completed, enrolled 24 healthy adult volunteers aged 18 years and older, and took place in Germany. It was a randomized, controlled study.
Flucloxacillin is a small molecule antibacterial developed for bacterial infections. It is classified in the infectious disease therapeutic area and was evaluated in a Phase 1 bioavailability study of 250 mg and 500 mg capsules in healthy volunteers. GSK plc, ticker GSK, is the developer.